Shaanxi Micot Pharmaceutical Technology Co., Ltd.HKEX: 2335

2026 Interim report

· Issued by Shaanxi Micot Pharmaceutical Technology Co., Ltd. via HKEXnews

Filed with HKEX · Stock code 2335 · · 82 pages · English and Chinese

Summary by 6ix AI

The report highlights significant losses attributed to increased research and development expenses, alongside a notable turnaround in cash flow from operating activities. Additionally, the company has made progress in clinical trials for its core product and other candidates, securing important regulatory recognitions and partnerships. The report also outlines the company's strategic focus on developing bi-/multi-specific peptide drugs for treating metabolic and cardiovascular diseases.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Shaanxi Micot Pharmaceutical Technology Co., Ltd. on 6ix

Earlier from Shaanxi Micot Pharmaceutical Technology

Later from Shaanxi Micot Pharmaceutical Technology

All Shaanxi Micot Pharmaceutical Technology news releases